Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events†
Version of Record online: 14 SEP 2009
Copyright © 2009 American Association for the Study of Liver Diseases
Volume 51, Issue 2, pages 615–620, February 2010
How to Cite
Lammert, C., Bjornsson, E., Niklasson, A. and Chalasani, N. (2010), Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology, 51: 615–620. doi: 10.1002/hep.23317
Potential conflict of interest: Nothing to report.
- Issue online: 25 JAN 2010
- Version of Record online: 14 SEP 2009
- Accepted manuscript online: 14 SEP 2009 12:00AM EST
- Manuscript Accepted: 3 SEP 2009
- Manuscript Received: 27 FEB 2009
- Public Health Service. Grant Number: K24DK069290
Additional Supporting Information may be found in the online version of this article.
|HEP_23317_sm_supptab.doc||37K||Supplemental Table 1: Most Commonly Prescribed Medications in the United States (2005) Categorized by Extent of Hepatic Metabolism|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.